RxSight (NASDAQ: RXST) details CFO sign-on bonus and corrects option vesting

Rhea-AI Filing Summary

RxSight, Inc. filed an amended report to update details about the compensation of its new Chief Financial Officer, Mark Wilterding. The company confirms that, under his employment agreement effective January 11, 2026, his cash sign-on bonus was set at $169,348.10 and paid on March 13, 2026, after payroll deductions and required withholding.

The amendment also corrects the vesting schedule for his stock option. 25% of the shares underlying the option will vest on the first anniversary of January 11, 2026, and the remaining shares will vest in equal monthly installments over the following three years, so that all option shares are fully vested four years from that date, subject to his continued employment and the terms of the option agreement. All other aspects of the original report remain unchanged.

true 0001111485 0001111485 2026-01-11 2026-01-11

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K/A

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 11, 2026

RxSight, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-40690		94-3268801
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

100 Columbia
Aliso Viejo, California		92656
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (949) 521-7830

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		RXST		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 12, 2026, RxSight, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Initial Report”) with the Securities and Exchange Commission to report, among other things, the appointment of Mark Wilterding as the Company’s Chief Financial Officer. The Company is filing this Current Report on Form 8-K/A to amend the Initial Report (i) to disclose certain compensation information related to Mr. Wilterding’s sign-on bonus that was not determinable at the time of the filing of the Initial Report and (ii) to correct the vesting schedule of the shares subject to the Option (as defined in the Initial Report).

As disclosed in the Initial Report, Mr. Wilterding entered into a confirmatory employment letter with the Company, dated December 15, 2025, effective as of January 11, 2026 (the “Employment Agreement”), and was entitled to receive a sign-on bonus in an amount determined based on terms specified in the Employment Agreement.

On March 10, 2026, the amount of Mr. Wilterding’s sign-on bonus was determined to be $169,348.10 based on the terms specified in the Employment Agreement. On March 13, 2026, the Company paid the sign-on bonus to Mr. Wilterding, less applicable payroll deductions and other required withholding.

This Current Report on Form 8-K/A is also being filed to correct the vesting schedule of the Option (as defined in the Initial Report). The shares subject to the Option are subject to vesting on the following terms: 25% of the shares subject to the Option will vest on the one-year anniversary of January 11, 2026, with the balance vesting equally monthly over the following three years, such that all of the shares subject to the Option will be fully vested four years from January 11, 2026, subject to Mr. Wilterding’s continued employment with the Company through each applicable vesting date and the terms of the applicable Option agreement.

Except as expressly set forth herein, this Current Report on Form 8-K/A does not amend the Initial Report in any way and does not modify or update any other disclosures contained in the Initial Report.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

						RxSight, Inc.
Date: March 19, 2026				By:		/s/ Ron Kurtz, M.D.
						Ron Kurtz, M.D. Chief Executive Officer and President

FAQ

What change is RxSight (RXST) reporting in this 8-K/A filing?

RxSight is amending a prior report to add final details of its CFO’s sign-on bonus and to correct the vesting schedule for his stock option. All other disclosures from the original filing remain unchanged.

How much is the RxSight (RXST) CFO Mark Wilterding’s sign-on bonus?

Mark Wilterding’s sign-on bonus was determined to be $169,348.10 based on his employment agreement. The company calculated the amount on March 10, 2026 and paid it on March 13, 2026, after required payroll deductions and tax withholdings.

When was the RxSight (RXST) CFO sign-on bonus paid?

The sign-on bonus for RxSight’s CFO, Mark Wilterding, was paid on March 13, 2026. This followed the determination of the exact bonus amount on March 10, 2026, pursuant to the terms of his December 15, 2025 employment agreement.

What is the corrected vesting schedule for the RxSight (RXST) CFO option grant?

The option vests 25% of the shares on the first anniversary of January 11, 2026. The remaining 75% vests in equal monthly installments over the next three years, so all shares vest over four years, subject to continued employment and the option agreement.

Does the RxSight (RXST) 8-K/A change any other terms of the CFO’s employment?

The amendment focuses only on specifying the final sign-on bonus amount and correcting the option vesting schedule. It does not alter other terms of Mark Wilterding’s employment or modify the other disclosures contained in the original report.

When did Mark Wilterding’s employment with RxSight (RXST) as CFO become effective?

Mark Wilterding’s employment as Chief Financial Officer became effective on January 11, 2026. His confirmatory employment letter with RxSight is dated December 15, 2025 and took effect as of that January 11, 2026 start date.

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 2.8 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 17.5 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 11.0 KB